# Hsp90B in Bladder Cancer

> **NIH NIH R01** · UNIVERSITY OF NOTRE DAME · 2020 · $351,703

## Abstract

The development of new methods to treat cancer is greatly needed. The Hsp90 protein folding machinery has
been the target of significant interest for the development of anti-cancer agents. However, Hsp90 is responsible for the folding of ~300 protein folding substrates, which may lead to undesired on-target toxicity and may be responsible for many of the Hsp90-targeted drugs that have failed in clinical trials. Through a structure-based approach, an isoform-selective inhibitor of Hsp90 has been identified and shown to exhibit good selectivity and affinity against particular cancers. Consequently, the goal of this application is to optimize this new inhibitory scaffold for great affinity/efficacy, to evaluate the role of a specific Hsp90 isoform in cancer, and to validate this isoform as a target for the treatment of bladder cancer.

## Key facts

- **NIH application ID:** 9922232
- **Project number:** 5R01CA222894-03
- **Recipient organization:** UNIVERSITY OF NOTRE DAME
- **Principal Investigator:** Brian S J Blagg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $351,703
- **Award type:** 5
- **Project period:** 2018-05-08 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9922232

## Citation

> US National Institutes of Health, RePORTER application 9922232, Hsp90B in Bladder Cancer (5R01CA222894-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9922232. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*